Patients with difficult to control hypertension typically require 2 or more agents to achieve goal blood pressure (BP) levels. Fixed-dose combination therapies with lower doses generally are well tolerated and more effective than higher-dose monotherapy. The authors performed prespecified and post hoc subgroup analyses of 2 double-blind, randomized, placebo-controlled trials that assessed the efficacy and safety of amlodipine and valsartan, alone and in combination, in patients with mild to moderate hypertension. Patients were randomized to amlodipine (study 1: 2.5 or 5 mg/d; study 2: 10 mg/d), valsartan (study 1: 40, 80, 160, or 320 mg/d; study 2: 160 or 320 mg/d), combination therapy across the same dose ranges, or placebo. Analyses were performed on changes from baseline in mean sitting systolic and diastolic BP and the occurrence of adverse events in specific subgroups of patients (ie, those with stage 2 hypertension [post hoc], the elderly [65 years or older], and blacks [both prespecified]). Amlodipine + valsartan combination therapy was associated with greater BP-lowering effects in the subgroups compared with each respective monotherapy and placebo. These findings were consistent with the primary efficacy analysis results from the overall study populations. Combination regimens were generally well tolerated by all patient subgroups.

译文

难以控制的高血压患者通常需要2种或更多种药物才能达到目标血压 (BP) 水平。较低剂量的固定剂量联合疗法通常比较高剂量的单一疗法具有良好的耐受性和更有效。作者对2项双盲,随机,安慰剂对照试验进行了预设和事后亚组分析,这些试验评估了氨氯地平和缬沙坦单独或联合使用对轻度至中度高血压患者的疗效和安全性。患者随机接受氨氯地平 (研究1: 2.5或5 mg/d; 研究2: 10 mg/d),缬沙坦 (研究1: 40、80、160或320 mg/d; 研究2: 160或320 mg/d),相同剂量范围内的联合治疗,或安慰剂。分析平均静坐收缩压和舒张压相对于基线的变化以及特定亚组患者 (即2期高血压 [事后],老年人 [65岁或以上] 和黑人 [均预先指定]) 中不良事件的发生。与每种单独疗法和安慰剂相比,氨氯地平 + 缬沙坦联合疗法在亚组中具有更大的BP降低作用。这些发现与总体研究人群的主要疗效分析结果一致。所有患者亚组对联合方案的耐受性普遍良好。

+1
+2
100研值 100研值 ¥99课程
检索文献一次
下载文献一次

去下载>

成功解锁2个技能,为你点赞

《SCI写作十大必备语法》
解决你的SCI语法难题!

技能熟练度+1

视频课《玩转文献检索》
让你成为检索达人!

恭喜完成新手挑战

手机微信扫一扫,添加好友领取

免费领《Endnote文献管理工具+教程》

微信扫码, 免费领取

手机登录

获取验证码
登录